Mediators of Inflammation / 2013 / Article / Tab 4

Clinical Study

Human Leukocyte Antigen Class II Alleles (DQB1 and DRB1) as Predictors for Response to Interferon Therapy in HCV Genotype 4

Table 4

Frequencies and percentages of linkage between HLA familial alleles in HCV patients and healthy group and in responder and nonresponder patients to combined treatment of interferon and ribavirin.

HaplotypesHCV patients
( )
Healthy controls
( )
P valueResponders
Nonresponders
P value

DQB1*02-DQB1*0315 (24.2%) 32 (56.1%)0.0159 (23.7%)6 (30%)0.754
DQB1*02-DQB1*053 (4.8%)10 (17.5%)0.3252 (5.3%)1 (5%)1.000
DQB1*02-DQB1*067 (11.3%)4 (7%)0.7245 (13.2%)2 (10%)1.000
DQB1*03-DQB1*055 (8.1%)10 (17.5%)0.8234 (10.5%)1 (5%)0.650
DQB1*03-DQB1*069 (14.5%)3 (5.3%)0.2128 (21.1%)1 (5%)0.143
DQB1*05-DQB1*062 (3.2%)4 (7%)0.4171 (2.6%)1 (5%)1.000
DQB1*02-DRB1*0311 (17.7%)2 (3.5%)0.1877 (18.4%)4 (20%)1.000
DQB1*02-DRB1*0715 (24.2%)35 (61.4%)0.00810 (26.3%)5 (25%)1.000
DQB1*02-DRB1*137 (11.3%)2 (3.5%)0.2226 (15.8%)1 (5%)0.403
DQB1*03-DRB1*0310 (16.2%)3 (5.3%)0.2506 (15.8%)4 (20%)0.724
DQB1*03-DRB1*0411 (17.7%)12 (21.1%)0.2195 (13.2%)6 (30%)0.163
DQB1*03-DRB1*0710 (16.2%)36 (63.2%)0.0006 (15.8%)4 (20%)0.724
DQB1*03-DRB1*1313 (21%)1 (1.8%)0.14711 (28.9%)2 (10%)0.184
DQB1*05-DRB1*012 (3.2%)6 (10.5%)0.4282 (5.3%)0 (0%)0.540
DQB1*05-DRB1*103 (4.8%)0 (0.0%)1.0003 (7.9%)0 (0%)0.544
DQB1*06-DRB1*159 (14.5%)4 (7%)0.3246 (15.8%)3 (15%)1.000
DRB1*03-DRB1*132 (3.2%)3 (5.3%)0.1732 (4.9%)0 (0%)0.545
DRB1*04-DRB1*113 (4.8%)7 (12.3%)0.7620 (0.0%)3 (14.3%)0.035#
DRB1*07-DRB1*134 (6.5%)2 (3.5%)0.0713 (7.9%)1 (4.8%)1.000
DRB1*07-DRB1*153 (4.8%)6 (10.5%)0.4211 (2.4%)2 (9.5%)0.263
DRB1*13-DRB1*142 (3.2%)0 (0.0%)0.5680 (0%)2 (9.5%)0.111
DRB1*13-DRB1*152 (3.2%)2 (3.5%)0.2472 (4.9%)0 (0%)0.545

Significant difference at PC ≤ 0.05 (corrected P after the Bonferroni correction) between responder and nonresponder patients to treatment. Significant difference at PC ≤ 0.05 (corrected P after the Bonferroni correction) between patients and healthy group. Each patient may have multiple suballeles or none at all, so that totals are not always equal to “ .”

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.